To the editor,
Thank you for taking the time to comment on our research article [1]. We acknowledge and appreciate your insightful comments [2].
You mentioned that randomized controlled trials are the gold standard for studying treatment adherence in fracture prevention, but there are problems with generalizability due to the high selection rate. As an alternative, we believe that using the actual cohort study method provides a high degree of generalizability.
Despite these advantages, this study had limitations in being able to identify only people with prescribed drugs, which was pointed out as a retrospective cohort study using the National Health Insurance Service data. As mentioned, drug possession does not guarantee actual drug use, so it is difficult to determine accurate drug compliance. Also, we agree with the opinion that a study on the cut-off point of treatment adherence of real-world studies for optimal therapeutic efficacy is needed in future research. Finally, it is also agreed that education and patient empowerment in the clinical setting would improve treatment outcomes.
Conflicts of interest
The authors declare no competing interests.
Acknowledgments
ORCID Seihee Kim: 0000-0001-9553-8142. Yoon-Sok Chung: 0000-0003-0179-4386. Yunhwan Lee: 0000-0001-8484-4750.
Footnotes
Peer review under responsibility of The Korean Society of Osteoporosis.
References
- 1.Kim S., Chung Y.-S., Lee Y. Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: a propensity score matching analysis. Osteoporos Sarcopenia. 2022;8:98–105. doi: 10.1016/j.afos.2022.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Cheung C.-L. Treatment adherence and risk of vertebral fracture. Osteoporos Sarcopenia. 2022;8:165. doi: 10.1016/j.afos.2022.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]